Clinical Trials
12 trialsNCT05642195 2026-06-05
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT05232916 2026-06-04
FLAMINGO-01
Greenwich LifeSciences, Inc.
Phase 3 Recruiting
NCT07178847 2026-06-03
NeckTAR-IN
Centre Jean Perrin
Phase NA Recruiting
NCT03876769 2026-06-02
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
NCT06500273 2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT05929222 2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT07136077 2026-06-01
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04521231 2026-05-28
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Active not recruiting
NCT06358430 2026-05-20
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07597252 2026-05-19
K4CARE-PDAC
Chang Gung Memorial Hospital
Not yet recruiting
NCT03326921 2026-05-18
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT07134088 2026-05-15
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Active not recruiting